Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain – Nature.com

Zhu, N. et al. A novel coronavirus from patients with pneumonia in china, 2019. N. Engl. J. Med. 382, 727733 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323, 12391242 (2020).

Article CAS PubMed Google Scholar

Booth, A. et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 16, e0247461 (2021).

Article CAS PubMed PubMed Central Google Scholar

Khoury, E. et al. Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: A Systematic Review and Meta-analysis. JAMA Netw. Open 5, e2210880 (2022).

Article PubMed PubMed Central Google Scholar

Salvatore, M. et al. COVID-19 Outcomes by cancer status, site, treatment, and vaccination. Cancer Epidemiol. Biomark. Prev. 32, 748759 (2023).

Article Google Scholar

Roel, E. et al. Cancer and the risk of coronavirus disease 2019 diagnosis, hospitalisation and death: a population-based multistate cohort study including 4 618 377 adults in Catalonia, Spain. Int. J. Cancer 150, 782794 (2022).

Article CAS PubMed Google Scholar

Oldani, S. et al. COVID-19 and lung cancer survival: an updated systematic review and meta-analysis. Cancers 14, 5706 (2022).

Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403416 (2021).

Article CAS PubMed Google Scholar

Falsey, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 385, 23482360 (2021).

Article CAS PubMed Google Scholar

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 26032615 (2020).

Article CAS PubMed Google Scholar

Thomas, S. J. et al. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine 40, 14831492 (2022).

Article CAS PubMed Google Scholar

Tran, S., Truong, T. H. & Narendran, A. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. Eur. J. Cancer 159, 259274 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zeng, C. et al. Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. medRxiv (2021) https://doi.org/10.1101/2021.10.20.21265273.

Peeters, M. et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open 6, 100274 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lasagna, A. et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open 6, 100272 (2021).

Article CAS PubMed PubMed Central Google Scholar

Martins-Branco, D. et al. Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 149, 16 (2022).

Palich, R. et al. High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers. Ann. Oncol. 32, 12941295 (2021).

Article CAS PubMed Google Scholar

Shroff, R. T. et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat. Med. 27, 20022011 (2021).

Article CAS PubMed PubMed Central Google Scholar

Thakkar, A. et al. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial. Elife 12, e83694 (2023).

Shapiro, L. C. et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell 40, 35 (2022).

Article CAS PubMed Google Scholar

Waldhorn, I. et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. 11, 24302435 (2021).

Article CAS PubMed Google Scholar

Macrae, K., Martinez-Cajas, J., Bessai, K., Abdulhamed, A. & Gong, Y. Quantitative analysis of SARS-CoV-2 antibody levels in cancer patients post three doses of immunization and prior to breakthrough COVID-19 infections. Curr. Oncol. 29, 70597071 (2022).

Article PubMed PubMed Central Google Scholar

Di Lorenzo, G. et al. The effect of vaccination against COVID-19 in cancer patients: final results of the COICA trial. Oncology 100, 512518 (2022).

Article PubMed Google Scholar

Pinato, D. J. et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. Eur. J. Cancer 171, 6474 (2022).

Article CAS PubMed PubMed Central Google Scholar

Rooney, A. et al. Risk of SARS-CoV-2 breakthrough infection in vaccinated cancer patients: A retrospective cohort study. J. Hematol. Oncol. 15, 67 (2022).

Article CAS PubMed PubMed Central Google Scholar

Simsek, M. et al. The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer. J. Med. Virol. 94, 41384143 (2022).

Article CAS PubMed PubMed Central Google Scholar

Hippisley-Cox, J. et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ 374, n2244 (2021).

Article PubMed Google Scholar

Mittelman, M. et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood 139, 14391451 (2022).

Article CAS PubMed PubMed Central Google Scholar

Starkey, T. et al. A population-scale temporal casecontrol evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP). Sci. Rep. 13, 11327 (2023).

Article CAS PubMed PubMed Central Google Scholar

Wu, J. T.-Y. et al. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US nationwide veterans affairs study. JAMA Oncol. 8, 281286 (2022).

Article PubMed Google Scholar

Lee, L. Y. W. et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 23, 748757 (2022).

Article CAS PubMed PubMed Central Google Scholar

Lee, L. Y. W. et al. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. Eur. J. Cancer 175, 110 (2022).

Article CAS PubMed PubMed Central Google Scholar

Mallah, N. et al. Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain. Environ. Res. 215, 114252 (2022).

Article CAS PubMed PubMed Central Google Scholar

Embi, P. J. et al. Effectiveness of 2-Dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 15531559 (2021).

Article CAS PubMed PubMed Central Google Scholar

Leuva, H. et al. Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: a prospective cohort study of U.S. veterans. Semin. Oncol. 49, 363370 (2022).

Article PubMed PubMed Central Google Scholar

Hernn, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758764 (2016).

Article PubMed PubMed Central Google Scholar

Wang, S. V. et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 13761385 (2023).

Article PubMed PubMed Central Google Scholar

Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 14121423 (2021).

Article CAS PubMed Google Scholar

Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088 (2021).

Article PubMed Google Scholar

Bignucolo, A. et al. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel) 9, 825 (2021).

Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 385, e84 (2021).

Article CAS PubMed Google Scholar

Zeng, C. et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell 40, 117119 (2022).

Article CAS PubMed Google Scholar

Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 Vaccines. Am. J. Epidemiol. 191, 800811 (2022).

Article PubMed Google Scholar

Atmar, R. L. et al. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med 386, 10461057 (2022).

Article CAS PubMed Google Scholar

Hulme, W. J. et al. Challenges in estimating the effectiveness of COVID-19 vaccination using observational data. Ann. Intern Med 176, 685693 (2023).

Article PubMed Google Scholar

Heg, T., Duriseti, R. & Prasad, V. Potential Healthy Vaccinee Bias in a study of BNT162b2 vaccine against Covid-19. N. Engl. J. Med 389, 284286 (2023).

Article PubMed Google Scholar

Xu, S. et al. A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. Vaccine 41, 844854 (2023).

Article CAS PubMed Google Scholar

Benn, C. S., Schaltz-Buchholzer, F., Nielsen, S., Netea, M. G. & Aaby, P. Randomized clinical trials of COVID-19 vaccines: do adenovirus-vector vaccines have beneficial non-specific effects? iScience 26, 106733 (2023).

Article ADS CAS PubMed PubMed Central Google Scholar

Recalde, M. et al. Validation of cancer diagnoses in electronic health records: results from the information system for research in primary care (SIDIAP) In Northeast Spain. Clin. Epidemiol. 11, 10151024 (2019).

Article PubMed PubMed Central Google Scholar

Dickerman, B. A. et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. veterans. N. Engl. J. Med. 386, 105115 (2022).

Article CAS PubMed Google Scholar

Magen, O. et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N. Engl. J. Med 386, 16031614 (2022).

Article CAS PubMed Google Scholar

Hitchings, M. D. T. et al. Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness. Epidemiology 33, 450456 (2022).

Article PubMed PubMed Central Google Scholar

Catal, M. et al. Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation. Int. J. Epidemiol. 53, dyad138 (2024).

Originally posted here:

Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain - Nature.com

Related Posts
Tags: